Clinical trial
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage
NCT02608411 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage
- Lead sponsor
- Istituto Oncologico Veneto IRCCS
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- February 19, 2016
- Completion date
- February 21, 2017
- Enrollment
- 5 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.